Karyopharm Therapeutics Inc.
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on
the discovery, development and commercialization of novel first-in-class drugs
targeting nuclear transport for the treatment of cancer and other major diseases.
Karyopharm's lead candidate is in ongoing clinical trials in multiple myeloma,
lymphoma, and solid tumors. The company is currently preparing for its first potential
U.S. commercial launch in 2019.